Long COVID symptoms: Study assesses 'symptom diary' of trial participants

Search continues for treatment that reduces long COVID symptoms: Study assesses 'symptom diary' of trial participants The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine. ... Weill Cornell Medical College Medical Xpress

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine. The study, published in eClinicalMedicine, details an international, multicenter phase 2/3 clinical trial that found a combination of amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms. ...

For this new study, the researchers assessed the "symptom diary" that trial participants kept for nine months after treatment, in which they recorded the severity of an array of 27 symptoms typical of long COVID. Participants also completed two health-related quality of life questionnaires.

The antibody combo continued to provide protection against hospitalization and death through this period. The researchers, however, saw no significant difference in the self-reported symptoms of long COVID for those who received treatment versus a placebo.

...